- Home
- TXT vs VTRS Comparison
TXT vs VTRS Comparison
Compare TXT & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXT
- VTRS
- Stock Information
- Founded
- TXT 1923
- VTRS 1961
- Country
- TXT United States
- VTRS United States
- Employees
- TXT N/A
- VTRS N/A
- Industry
- TXT Aerospace
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- TXT Industrials
- VTRS Health Care
- Exchange
- TXT Nasdaq
- VTRS Nasdaq
- Market Cap
- TXT N/A
- VTRS 9.0B
- IPO Year
- TXT N/A
- VTRS N/A
- Fundamental
- Price
- TXT $72.22
- VTRS $9.09
- Analyst Decision
- TXT Hold
- VTRS Hold
- Analyst Count
- TXT 9
- VTRS 4
- Target Price
- TXT $87.33
- VTRS $10.50
- AVG Volume (30 Days)
- TXT 1.5M
- VTRS 13.5M
- Earning Date
- TXT 04-24-2025
- VTRS 05-08-2025
- Dividend Yield
- TXT 0.11%
- VTRS 5.28%
- EPS Growth
- TXT N/A
- VTRS N/A
- EPS
- TXT 4.44
- VTRS N/A
- Revenue
- TXT $13,873,000,000.00
- VTRS $14,330,200,000.00
- Revenue This Year
- TXT $7.85
- VTRS N/A
- Revenue Next Year
- TXT $4.52
- VTRS $1.20
- P/E Ratio
- TXT $15.83
- VTRS N/A
- Revenue Growth
- TXT 0.57
- VTRS N/A
- 52 Week Low
- TXT $57.70
- VTRS $6.85
- 52 Week High
- TXT $94.57
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- TXT 60.81
- VTRS 65.82
- Support Level
- TXT $69.46
- VTRS $8.47
- Resistance Level
- TXT $72.06
- VTRS $8.76
- Average True Range (ATR)
- TXT 1.81
- VTRS 0.27
- MACD
- TXT 0.65
- VTRS 0.17
- Stochastic Oscillator
- TXT 90.83
- VTRS 76.96
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.